KVUE Quote, Financials, Valuation and Earnings

Grove Collaborative Holdings has a net margin of 8% compared to Kenvue's net margin of -25.53%. Kenvue's return on equity of 9.84% beat Grove Collaborative Holdings's return on equity of -154.22%.

Kenvue has a consensus price target of $24.00, signalling upside risk potential of 2.97%. On the other hand Grove Collaborative Holdings has an analysts' consensus of $2.50 which suggests that it could grow by 61.29%. Given that Grove Collaborative Holdings has higher upside potential than Kenvue, analysts believe Grove Collaborative Holdings is more attractive than Kenvue.

Kenvue has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Grove Collaborative Holdings has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Kenvue has a quarterly dividend of $0.21 per share corresponding to a yield of 3.5%. Grove Collaborative Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kenvue pays 150.68% of its earnings as a dividend. Grove Collaborative Holdings pays out -- of its earnings as a dividend.

Kenvue quarterly revenues are $3.7B, which are larger than Grove Collaborative Holdings quarterly revenues of $49.5M. Kenvue's net income of $293M is higher than Grove Collaborative Holdings's net income of -$12.6M. Notably, Kenvue's price-to-earnings ratio is 43.98x while Grove Collaborative Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kenvue is 2.90x versus 0.28x for Grove Collaborative Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Hims & Hers Health has a net margin of 8% compared to Kenvue's net margin of 5.41%. Kenvue's return on equity of 9.84% beat Hims & Hers Health's return on equity of 32.03%.

Kenvue has a consensus price target of $24.00, signalling upside risk potential of 2.97%. On the other hand Hims & Hers Health has an analysts' consensus of $44.16 which suggests that it could grow by 27.09%. Given that Hims & Hers Health has higher upside potential than Kenvue, analysts believe Hims & Hers Health is more attractive than Kenvue.

Kenvue has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Hims & Hers Health has a beta of 1.368, suggesting its more volatile than the S&P 500 by 36.817%.

Kenvue has a quarterly dividend of $0.21 per share corresponding to a yield of 3.5%. Hims & Hers Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kenvue pays 150.68% of its earnings as a dividend. Hims & Hers Health pays out -- of its earnings as a dividend.

Kenvue quarterly revenues are $3.7B, which are larger than Hims & Hers Health quarterly revenues of $481.1M. Kenvue's net income of $293M is higher than Hims & Hers Health's net income of $26M. Notably, Kenvue's price-to-earnings ratio is 43.98x while Hims & Hers Health's PE ratio is 64.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kenvue is 2.90x versus 5.57x for Hims & Hers Health. Usually stocks with elevated PS ratios are considered overvalued.

The Beauty Health has a net margin of 8% compared to Kenvue's net margin of -12.37%. Kenvue's return on equity of 9.84% beat The Beauty Health's return on equity of -47.95%.

Kenvue has a consensus price target of $24.00, signalling upside risk potential of 2.97%. On the other hand The Beauty Health has an analysts' consensus of $1.58 which suggests that it could grow by 20.23%. Given that The Beauty Health has higher upside potential than Kenvue, analysts believe The Beauty Health is more attractive than Kenvue.

Kenvue has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison The Beauty Health has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Kenvue has a quarterly dividend of $0.21 per share corresponding to a yield of 3.5%. The Beauty Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kenvue pays 150.68% of its earnings as a dividend. The Beauty Health pays out -- of its earnings as a dividend.

Kenvue quarterly revenues are $3.7B, which are larger than The Beauty Health quarterly revenues of $83.5M. Kenvue's net income of $293M is higher than The Beauty Health's net income of -$10.3M. Notably, Kenvue's price-to-earnings ratio is 43.98x while The Beauty Health's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kenvue is 2.90x versus 0.54x for The Beauty Health. Usually stocks with elevated PS ratios are considered overvalued.

Waldencast PLC has a net margin of 8% compared to Kenvue's net margin of --. Kenvue's return on equity of 9.84% beat Waldencast PLC's return on equity of -5.64%.

Kenvue has a consensus price target of $24.00, signalling upside risk potential of 2.97%. On the other hand Waldencast PLC has an analysts' consensus of $5.38 which suggests that it could grow by 72.99%. Given that Waldencast PLC has higher upside potential than Kenvue, analysts believe Waldencast PLC is more attractive than Kenvue.

Kenvue has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Waldencast PLC has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Kenvue has a quarterly dividend of $0.21 per share corresponding to a yield of 3.5%. Waldencast PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kenvue pays 150.68% of its earnings as a dividend. Waldencast PLC pays out -- of its earnings as a dividend.

Kenvue quarterly revenues are $3.7B, which are larger than Waldencast PLC quarterly revenues of --. Kenvue's net income of $293M is higher than Waldencast PLC's net income of --. Notably, Kenvue's price-to-earnings ratio is 43.98x while Waldencast PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kenvue is 2.90x versus 1.24x for Waldencast PLC. Usually stocks with elevated PS ratios are considered overvalued.